Multivalent canine distemper virus vaccine
AssigneeDiamond Scientific Co.
InventorsEdmund P. Bass, William H. Kelsey
Life of this patent
Estimating the term…
Abstract
A vaccine composition for animals susceptible to infection by canine distemper virus. The vaccine comprises a small but immunologically effective amount of an inactivated canine distemper virus in combination with a non-toxic pharmaceutically acceptable immunologic adjuvant. A preferred method of inactivation of canine distemper virus by either exposure of the virus to an inactivating effective amount of binary ethyleneimine or alternatively exposure of the virus to long wavelength ultraviolet light in the presence of a furocoumarin.
Claims9
A multivalent composition for animals susceptible to infection by canine distemper virus comprising:
- a small but immunologically effective amount canine distemper virus which although inactivated substantially retains its immunogenicity;
- and
- a small but immunologically effective amount of an inactivated previously infectious material which although inactivated substantially retains its immunogenicity, said materials being selected from the group consisting of canine adenovirus type 2, canine parainfluenza virus, canine parvovirus, infectious canine hepatitis and bacterins leptospira canicola and leptospira icterohaemorrhagiae.
The method for protecting mammals from infection caused by canine distemper virus as well as certain other common infectious pathogens for mammals of canine origin, said method comprising:
- administering to said mammal a vaccine composition containing a small but immunologically effective amount of an inactivated canine distemper virus which although inactivated substantially retains its immunogenicity;
- a small but immunologically effective amount of an inactivated infectious pathogen selected from the group consisting of canine adenovirus type 2, canine parainfluenza virus, canine parvovirus, infectious canine hepatitis leptospira canicola and leptospira icteroheamorrhagiae which although inactivated substantially retains its immunogenicity;
- and
- said inactivated virus and pathogen being in combination with a non-toxic pharmaceutically acceptable immunologic adjuvant.
Dependencies are inferred from the claim text.